Cargando…

Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes

Background: Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. A unique approach to target and kill colon, prostate, and other epithelial-type cancer cells in the blood has been recently developed that uses circulating leukocytes to present the cancer-specific,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lederman, Emily E., Hope, Jacob M., King, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232872/
https://www.ncbi.nlm.nih.gov/pubmed/30460191
http://dx.doi.org/10.3389/fonc.2018.00410
_version_ 1783370473479864320
author Lederman, Emily E.
Hope, Jacob M.
King, Michael R.
author_facet Lederman, Emily E.
Hope, Jacob M.
King, Michael R.
author_sort Lederman, Emily E.
collection PubMed
description Background: Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. A unique approach to target and kill colon, prostate, and other epithelial-type cancer cells in the blood has been recently developed that uses circulating leukocytes to present the cancer-specific, liposome-bound Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) on their surface along with E − selectin adhesion receptors. This approach, demonstrated both in vitro with human blood and in mice, mimics the cytotoxic activity of natural killer cells. The resulting liposomal TRAIL-coated leukocytes hold promise as an effective means to neutralize circulating tumor cells that enter the bloodstream with the potential to form new metastases. Methods: The computational biology study reported here examines the mechanism of this effective signal delivery, by considering the kinetics of the coupled reaction cascade, from TRAIL binding death receptor to eventual apoptosis. In this study, a collision of bound TRAIL with circulating tumor cells (CTCs) is considered and compared to a prolonged exposure of CTCs to soluble TRAIL. An existing computational model of soluble TRAIL treatment was modified to represent the kinetics from a diffusion-limited 3D reference frame into a 2D collision frame with advection and adhesion to mimic the E − selectin and membrane bound TRAIL treatment. Thus, the current model recreates the new approach of targeting cancer cells within the blood. The model was found to faithfully reproduce representative observations from experiments of liposomal TRAIL treatment under shear. Results: The model predicts apoptosis of CTCs within 2 h when treated with membrane bound TRAIL, while apoptosis in CTCs treated with soluble TRAIL proceeds much more slowly over the course of 10 h, consistent with previous experiments. Given the clearance rate of soluble TRAIL in vivo, this model predicts that the soluble TRAIL method would be rendered ineffective, as found in previous experiments. Conclusion: This study therefore indicates that the kinetics of the coupled reaction cascade of liposomal E − selectin and membrane bound TRAIL colliding with CTCs can explain why this new approach to target and kill cancer cells in blood is much more effective than its soluble counterpart.
format Online
Article
Text
id pubmed-6232872
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62328722018-11-20 Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes Lederman, Emily E. Hope, Jacob M. King, Michael R. Front Oncol Oncology Background: Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. A unique approach to target and kill colon, prostate, and other epithelial-type cancer cells in the blood has been recently developed that uses circulating leukocytes to present the cancer-specific, liposome-bound Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) on their surface along with E − selectin adhesion receptors. This approach, demonstrated both in vitro with human blood and in mice, mimics the cytotoxic activity of natural killer cells. The resulting liposomal TRAIL-coated leukocytes hold promise as an effective means to neutralize circulating tumor cells that enter the bloodstream with the potential to form new metastases. Methods: The computational biology study reported here examines the mechanism of this effective signal delivery, by considering the kinetics of the coupled reaction cascade, from TRAIL binding death receptor to eventual apoptosis. In this study, a collision of bound TRAIL with circulating tumor cells (CTCs) is considered and compared to a prolonged exposure of CTCs to soluble TRAIL. An existing computational model of soluble TRAIL treatment was modified to represent the kinetics from a diffusion-limited 3D reference frame into a 2D collision frame with advection and adhesion to mimic the E − selectin and membrane bound TRAIL treatment. Thus, the current model recreates the new approach of targeting cancer cells within the blood. The model was found to faithfully reproduce representative observations from experiments of liposomal TRAIL treatment under shear. Results: The model predicts apoptosis of CTCs within 2 h when treated with membrane bound TRAIL, while apoptosis in CTCs treated with soluble TRAIL proceeds much more slowly over the course of 10 h, consistent with previous experiments. Given the clearance rate of soluble TRAIL in vivo, this model predicts that the soluble TRAIL method would be rendered ineffective, as found in previous experiments. Conclusion: This study therefore indicates that the kinetics of the coupled reaction cascade of liposomal E − selectin and membrane bound TRAIL colliding with CTCs can explain why this new approach to target and kill cancer cells in blood is much more effective than its soluble counterpart. Frontiers Media S.A. 2018-10-29 /pmc/articles/PMC6232872/ /pubmed/30460191 http://dx.doi.org/10.3389/fonc.2018.00410 Text en Copyright © 2018 Lederman, Hope and King. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lederman, Emily E.
Hope, Jacob M.
King, Michael R.
Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title_full Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title_fullStr Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title_full_unstemmed Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title_short Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes
title_sort mass action kinetic model of apoptosis by trail-functionalized leukocytes
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232872/
https://www.ncbi.nlm.nih.gov/pubmed/30460191
http://dx.doi.org/10.3389/fonc.2018.00410
work_keys_str_mv AT ledermanemilye massactionkineticmodelofapoptosisbytrailfunctionalizedleukocytes
AT hopejacobm massactionkineticmodelofapoptosisbytrailfunctionalizedleukocytes
AT kingmichaelr massactionkineticmodelofapoptosisbytrailfunctionalizedleukocytes